BetaShares S&P/ASX Australian Technology ETF (ATEC)
CXA 
Summary
Alphatec - Slower Growth Seems Priced In Here
Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability.
Alphatec Holdings, Inc. (ATEC) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Alphatec Holdings, Inc. (ATEC) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Alphatec Holdings, Inc. (ATEC) Q1 2026 Earnings Call Transcript
Alphatec Holdings, Inc. (ATEC) Q1 2026 Earnings Call Transcript
BetaShares S&P/ASX Australian Technology ETF (ATEC) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BetaShares S&P/ASX Australian Technology ETF ever had a stock split?
BetaShares S&P/ASX Australian Technology ETF Profile
| CXA Exchange | US Country |
Overview
Alphatec Holdings, Inc., founded in 1990 and headquartered in Carlsbad, California, is a distinguished medical technology company focused on the design, development, and commercialization of innovative technologies for the surgical treatment of spinal disorders. Operating both in the United States and internationally, Alphatec manufactures and supplies its revolutionary products through a combination of third-party suppliers, independent sales agents, and direct sales representatives. The company's commitment to advancing spinal surgery technologies has positioned it as a leader in its field, offering a wide range of solutions aimed at improving patient outcomes.
Products and Services
- Alpha InformatiX Product Platform – A comprehensive suite of solutions that includes:
- EOS imaging system: Offers full-body imaging for enhanced diagnostic capabilities.
- VEA alignment mobile application: Leverages EOS technology, enabling quick quantification of alignment parameters on mobile devices.
- SafeOp Neural InformatiX System: Automates electromyographic and somatosensory evoked potential monitoring for increased safety.
- Valence: Integrates navigation and robotics into spine procedures, optimizing surgical outcomes.
- Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems – Designed to improve accessibility and patient positioning during surgery.
- Spinal Implants and Fixation Systems – Includes:
- NanoTec surface modifications: Enhance implant integration and stability.
- Calibrate PSX and Invictus: Offer advanced spinal fixation solutions.
- Standalone implants: Provide options for height restoration and stabilization.
- Biological Solutions – A diverse portfolio of biologics designed to support spinal surgery and healing, comprising:
- 3D ProFuse Osteoconductive Bioscaffold: Facilitates ease of handling and improved endplate contact.
- AlphaGRAFT Demineralized Bone Matrix (DBM): Utilizes demineralized human tissues for bone grafting.
- AlphaGRAFT DBM Fibers: Offers demineralized fibers for versatile use in bone grafts.
- AlphaGRAFT Cellular Bone Matrix (CBM): A growth factor-enriched cellular bone matrix available in various forms for different surgical needs.
- BioCORE Moldable Bioactive Graft: A moldable, synthetic mineral-collagen composite matrix designed to fit bone defects.
- Amnioshield Amniotic Tissue Barrier: An allograft used for spinal surgical barrier applications.
